Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene Therapy.

Blood·2026
Same author

Multi-omic profiling of human antibody-secreting cells reveals diverse subsets sustain durable humoral immunity.

bioRxiv : the preprint server for biology·2026
Same author

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.

Journal of hematology & oncology·2026
Same author

Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response.

Nature communications·2026
Same author

CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation.

Blood·2026
Same author

Cytomegalovirus Lymphadenitis Mimicking Relapsed Lymphoma After CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica·2026

Related Experiment Video

Updated: Jul 11, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Pretargeted radioimmunotherapy for B-cell lymphomas.

Damian J Green1, John M Pagel, Anastasia Pantelias

  • 1Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, Washington 98109, USA. dgreen@fhcrc.org

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 19, 2007
PubMed
Summary

Pretargeted radioimmunotherapy offers a superior treatment for relapsed B-cell lymphomas. This innovative approach demonstrated better tumor regression and longer survival in preclinical models compared to conventional methods.

More Related Videos

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: Jul 11, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

  • Oncology
  • Immunotherapy
  • Radiochemistry

Background:

  • Relapsed or treatment-refractory B-cell lymphomas remain incurable with standard treatments.
  • While high-dose chemoradiotherapy and stem cell transplantation offer some cures, most patients succumb to progressive disease.

Purpose of the Study:

  • To investigate the efficacy of pretargeted radioimmunotherapy (PRIT) for treating lymphomas.
  • To compare PRIT with conventional radioimmunotherapy in preclinical models.

Main Methods:

  • Utilized monoclonal antibody-streptavidin conjugates and fusion proteins for PRIT.
  • Employed a dendrimeric clearing agent and radiometal-labeled chelators for enhanced targeting.
  • Targeted cell surface antigens including CD20, CD22, CD45, and HLA-DR in mouse and primate models.

Main Results:

  • PRIT demonstrated superior biodistributions compared to conventional radioimmunotherapy.
  • Achieved more complete tumor regressions and significantly longer survival across all targeted antigens.
  • Preclinical models showed marked advantages for the PRIT strategy.

Conclusions:

  • Pretargeted radioimmunotherapy is a highly effective strategy for B-cell lymphomas.
  • This novel approach holds promise for significantly prolonging survival in patients with refractory lymphomas.